Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.

Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J; Spanish Society of Pulmonology and Thoracic Surgery.

Arch Bronconeumol. 2012 Jul;48(7):247-57. doi: 10.1016/j.arbres.2012.04.001. Epub 2012 May 3. English, Spanish.

2.

[Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].

Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J.

Aten Primaria. 2012 Jul;44(7):425-37. doi: 10.1016/j.aprim.2012.04.005. Epub 2012 Jun 15. Spanish.

3.

[Clinical profile of roflumilast].

Izquierdo Alonso JL.

Arch Bronconeumol. 2010 Dec;46 Suppl 10:25-32. doi: 10.1016/S0300-2896(10)70053-3. Review. Spanish.

4.

A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC).

Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Piñera P, Simón A, Riesco JA, Ancochea J, Soriano JB.

Prim Care Respir J. 2013 Mar;22(1):117-21. doi: 10.4104/pcrj.2013.00016.

5.

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Antoniu SA.

Curr Opin Investig Drugs. 2006 May;7(5):412-7. Review.

PMID:
16729716
6.

Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Miravitlles M, Calle M, Soler-Cataluña JJ.

Arch Bronconeumol. 2012 Mar;48(3):86-98. doi: 10.1016/j.arbres.2011.10.007. Epub 2011 Dec 22. Review. English, Spanish.

7.

The use of roflumilast in COPD: a primary care perspective.

Price D, Chisholm A, Ryan D, Crockett A, Jones R.

Prim Care Respir J. 2010 Dec;19(4):342-51. doi: 10.4104/pcrj.2010.00066. Review. Erratum in: Prim Care Respir J. 2011 Mar;20(1):45.

8.

[Toward personalized and integrated treatment of patients with COPD].

Ancochea J, Gómez García T, de Miguel Díez J.

Arch Bronconeumol. 2010 Dec;46 Suppl 10:14-8. doi: 10.1016/S0300-2896(10)70051-X. Review. Spanish.

9.

Current drug treatment, chronic and acute.

Calverley P.

Clin Chest Med. 2014 Mar;35(1):177-89. doi: 10.1016/j.ccm.2013.09.009. Review.

PMID:
24507845
10.

Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.

Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Antonio Riesco J, Simonet P, Rigau D, Soriano JB, Ancochea J.

Arch Bronconeumol. 2017 Jun;53(6):324-335. doi: 10.1016/j.arbres.2017.03.018. Epub 2017 May 3. English, Spanish.

11.

[Phosphodiesterase-4 inhibitors: roflumilast].

Izquierdo Alonso JL.

Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X. Review. Spanish.

PMID:
21596170
12.

[Pharmacological treatment of COPD. Where are we now?].

Calle Rubio M, Pinedo Sierra C, Rodríguez Hermosa JL.

Arch Bronconeumol. 2010 Dec;46 Suppl 10:3-7. doi: 10.1016/S0300-2896(10)70049-1. Review. Spanish.

13.

[Moving towards a new focus on COPD. The Spanish COPD Guidelines (GESEPOC)].

Grupo de Trabajo de GESEPOC.

Arch Bronconeumol. 2011 Aug;47(8):379-81. doi: 10.1016/j.arbres.2011.05.008. Epub 2011 Jul 14. Spanish. No abstract available.

14.

[Chronic obstructive pulmonary disease : new pharmacotherapeutic options].

Greulich T, Koczulla AR, Vogelmeier C.

Internist (Berl). 2012 Nov;53(11):1364-70, 1373-5. doi: 10.1007/s00108-012-3119-1. German.

PMID:
22955248
15.

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype.

Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Sheen SS, Kim N, Seo JB, Oh YM, Lee SD.

Respir Med. 2010 Apr;104(4):542-9. doi: 10.1016/j.rmed.2009.10.024. Epub 2009 Nov 17.

16.

Phenotype/endotype-driven therapy in COPD: potential economic implications.

Antoniu SA.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):421-3. doi: 10.1586/14737167.2013.815402. No abstract available.

PMID:
23977968
17.

Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice.

Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB.

Eur Respir J. 2013 Jun;41(6):1252-6. doi: 10.1183/09031936.00118912. Epub 2012 Oct 11.

18.

[Pharmacological treatment of COPD and future of anti-inflammatory therapy].

Watz H, Bitter-Suermann S, Kanniess F, Magnussen H.

Med Klin (Munich). 2006 Apr 15;101(4):283-92. Review. German.

PMID:
16607484
19.

[Pharmacological management of stable COPD].

Rauscher H.

Wien Med Wochenschr. 2005 Mar;155(5-6):95-100. Review. German.

PMID:
15884489
20.

[Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].

Shmelev EI, Shmeleva NM.

Ter Arkh. 2012;84(6):73-6. Russian.

PMID:
22997924

Supplemental Content

Support Center